All In Biotech

Drug Trial Radar · NCT01523171

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib

A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Last checked: Nov 21, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

97

Actual

Start

Apr 30, 2012

Primary completion

Apr 30, 2014

Study completion Apr 30, 2014

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Feb 1, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: \- To evaluate the efficacy of once daily dose of SAR302503 in subjects previously treated with ruxolitinib and with a current diagnosis of intermediate-1 with symptoms, Intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (Post-PV MF), or post-essential thrombocythemia myelofibrosis (Post-ET MF) based on the reduction of spleen volume at the end of 6 treatment cycles; Secondary Objectives: * To evaluate the effect of SAR302503 on Myelofibrosis (MF) associated symptoms as measured by the modified Myelofibrosis Symptom Assessment Form (MFSAF) diary * To evaluate the durability of splenic response * To evaluate the splenic response to SAR302503 by palpation at the end of Cycle 6 * To evaluate the splenic response to SAR302503 at the end of Cycle 3 * To evaluate the effect of SAR302503 on the Janus kinase 2 (JAK2) V617F allele burden * To evaluate the safety and tolerability of SAR302503 in this population * To evaluate plasma concentrations of SAR302503 for population PK analysis, if warranted

Conditions

  • Hematopoietic Neoplasm

Interventions

  • SAR302503Drug

    Pharmaceutical form:capsule Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response Rate: Percentage of Participants With >=35% Reduction From Baseline in Spleen Volume at End of Cycle 6Time frame: Baseline, End of Cycle 6

Locations

42 sites in 10 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840007

    Phoenix, Arizona

  • Investigational Site Number 840003

    San Francisco, California

  • Investigational Site Number 840004

    San Francisco, California

  • Investigational Site Number 840005

    Atlanta, Georgia

  • Investigational Site Number 840014

    Chicago, Illinois

  • Investigational Site Number 840001

    Kansas City, Kansas

  • Investigational Site Number 840017

    Baltimore, Maryland

  • Investigational Site Number 840013

    Baltimore, Maryland

  • Investigational Site Number 840010

    Ann Arbor, Michigan

  • Investigational Site Number 840009

    New York, New York

  • Investigational Site Number 840018

    New York, New York

  • Investigational Site Number 840022

    Cleveland, Ohio

  • Investigational Site Number 840019

    Middletown, Ohio

  • Investigational Site Number 840024

    Charleston, South Carolina

  • Investigational Site Number 840002

    Houston, Texas

  • Investigational Site Number 840015

    Salt Lake City, Utah

  • Investigational Site Number 040002

    Salzburg, Austria

  • Investigational Site Number 040001

    Vienna, Austria

  • Investigational Site Number 056002

    Antwerp, Belgium

  • Investigational Site Number 056003

    Leuven, Belgium

  • Investigational Site Number 124001

    Toronto, Canada

  • Investigational Site Number 250001

    Marseille, France

  • Investigational Site Number 250003

    Nîmes, France

  • Investigational Site Number 250002

    Paris, France

  • Investigational Site Number 250006

    Paris, France

  • Investigational Site Number 250004

    Toulouse, France

  • Investigational Site Number 276003

    Frankfurt am Main, Germany

  • Investigational Site Number 276007

    Leipzig, Germany

  • Investigational Site Number 276006

    Magdeburg, Germany

  • Investigational Site Number 276001

    Mannheim, Germany

  • Investigational Site Number 276005

    Ulm, Germany

  • Investigational Site Number 380004

    Florence, Italy

  • Investigational Site Number 380001

    Milan, Italy

  • Investigational Site Number 380002

    Roma, Italy

  • Investigational Site Number 380003

    Varese, Italy

  • Investigational Site Number 528002

    Amsterdam, Netherlands

  • Investigational Site Number 528003

    Maastricht, Netherlands

  • Investigational Site Number 528001

    Nijmegen, Netherlands

  • Investigational Site Number 724001

    Barcelona, Spain

  • Investigational Site Number 724003

    Majadahonda, Spain

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.